Corticosteroid medication in treatment of a sudden inflammation of the voice box among vocal professionals

Corticosteroid in treatment of acute laryngitis among vocal professionals

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-006497-23-FI

Enrollment

Registered

2022-01-25

Start date

2022-07-05

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngitis

Interventions

Trade Name: Prednisolon Product Name: Prednisolon Pharmaceutical Form: Tablet INN or Proposed INN: Prednisolone Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Akuutti laryngiitti Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 70 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Lääkeaineen kontraindikaatiot. Hiivainen laryngiitti sekä märkäinen bakteerilaryngiitti. Raskaus ja imetys.

Design outcomes

Primary

Measure	Time frame
Main Objective: Kurkunpäätulehduksen paraneminen. ;Secondary Objective: Äänen paraneminen. ;Primary end point(s): Laryngiitin paraneminen. ;Timepoint(s) of evaluation of this end point: 6 weeks	—

Secondary

Measure	Time frame
Secondary end point(s): Äänen paraneminen;Timepoint(s) of evaluation of this end point: 6 weeks	—

Countries

Finland

Contacts

Public Contactno

annika.laaksonen1@gmail.com

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026